nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—ALB—acquired immunodeficiency syndrome	0.212	1	CbGaD
Naproxen—UGT1A1—Abacavir—acquired immunodeficiency syndrome	0.0756	0.131	CbGbCtD
Naproxen—UGT2B7—Zidovudine—acquired immunodeficiency syndrome	0.041	0.0711	CbGbCtD
Naproxen—SLC22A6—Stavudine—acquired immunodeficiency syndrome	0.0396	0.0687	CbGbCtD
Naproxen—SLCO1A2—Indinavir—acquired immunodeficiency syndrome	0.0309	0.0536	CbGbCtD
Naproxen—SLC22A6—Didanosine—acquired immunodeficiency syndrome	0.03	0.0521	CbGbCtD
Naproxen—SLCO1A2—Nelfinavir—acquired immunodeficiency syndrome	0.03	0.052	CbGbCtD
Naproxen—SLCO1A2—Saquinavir—acquired immunodeficiency syndrome	0.0271	0.047	CbGbCtD
Naproxen—SLCO1A2—Ritonavir—acquired immunodeficiency syndrome	0.0271	0.047	CbGbCtD
Naproxen—SLC22A6—Zidovudine—acquired immunodeficiency syndrome	0.0158	0.0274	CbGbCtD
Naproxen—CYP2C8—Amprenavir—acquired immunodeficiency syndrome	0.0143	0.0248	CbGbCtD
Naproxen—CYP2C8—Delavirdine—acquired immunodeficiency syndrome	0.0143	0.0248	CbGbCtD
Naproxen—ALB—Saquinavir—acquired immunodeficiency syndrome	0.014	0.0243	CbGbCtD
Naproxen—ALB—Zidovudine—acquired immunodeficiency syndrome	0.0134	0.0233	CbGbCtD
Naproxen—CYP1A2—Efavirenz—acquired immunodeficiency syndrome	0.013	0.0226	CbGbCtD
Naproxen—CYP1A2—Lopinavir—acquired immunodeficiency syndrome	0.0122	0.0212	CbGbCtD
Naproxen—CYP1A2—Nevirapine—acquired immunodeficiency syndrome	0.0122	0.0212	CbGbCtD
Naproxen—SLC22A6—Lamivudine—acquired immunodeficiency syndrome	0.0122	0.0212	CbGbCtD
Naproxen—CYP2C9—Efavirenz—acquired immunodeficiency syndrome	0.0117	0.0203	CbGbCtD
Naproxen—CYP1A2—Delavirdine—acquired immunodeficiency syndrome	0.0111	0.0192	CbGbCtD
Naproxen—CYP2C9—Nevirapine—acquired immunodeficiency syndrome	0.011	0.0191	CbGbCtD
Naproxen—CYP2C9—Lopinavir—acquired immunodeficiency syndrome	0.011	0.0191	CbGbCtD
Naproxen—CYP2C8—Ritonavir—acquired immunodeficiency syndrome	0.0108	0.0188	CbGbCtD
Naproxen—CYP2C8—Saquinavir—acquired immunodeficiency syndrome	0.0108	0.0188	CbGbCtD
Naproxen—CYP2C8—Zidovudine—acquired immunodeficiency syndrome	0.0104	0.018	CbGbCtD
Naproxen—CYP2C9—Amprenavir—acquired immunodeficiency syndrome	0.00996	0.0173	CbGbCtD
Naproxen—CYP2C9—Delavirdine—acquired immunodeficiency syndrome	0.00996	0.0173	CbGbCtD
Naproxen—CYP1A2—Nelfinavir—acquired immunodeficiency syndrome	0.00926	0.0161	CbGbCtD
Naproxen—CYP2C9—Indinavir—acquired immunodeficiency syndrome	0.0086	0.0149	CbGbCtD
Naproxen—CYP1A2—Ritonavir—acquired immunodeficiency syndrome	0.00838	0.0145	CbGbCtD
Naproxen—CYP2C9—Nelfinavir—acquired immunodeficiency syndrome	0.00835	0.0145	CbGbCtD
Naproxen—CYP2C9—Saquinavir—acquired immunodeficiency syndrome	0.00755	0.0131	CbGbCtD
Naproxen—CYP2C9—Ritonavir—acquired immunodeficiency syndrome	0.00755	0.0131	CbGbCtD
Naproxen—CYP2C9—Zidovudine—acquired immunodeficiency syndrome	0.00724	0.0126	CbGbCtD
Naproxen—UGT1A1—blood plasma—acquired immunodeficiency syndrome	0.00176	0.0753	CbGeAlD
Naproxen—CYP2C8—blood plasma—acquired immunodeficiency syndrome	0.000834	0.0356	CbGeAlD
Naproxen—UGT2B7—digestive system—acquired immunodeficiency syndrome	0.000797	0.0341	CbGeAlD
Naproxen—CYP1A2—blood plasma—acquired immunodeficiency syndrome	0.000781	0.0334	CbGeAlD
Naproxen—PTGS1—endothelium—acquired immunodeficiency syndrome	0.000762	0.0325	CbGeAlD
Naproxen—CYP2C9—blood plasma—acquired immunodeficiency syndrome	0.000741	0.0317	CbGeAlD
Naproxen—PTGS2—endothelium—acquired immunodeficiency syndrome	0.000728	0.0311	CbGeAlD
Naproxen—AKR1C3—blood—acquired immunodeficiency syndrome	0.0007	0.0299	CbGeAlD
Naproxen—UGT1A1—digestive system—acquired immunodeficiency syndrome	0.000678	0.029	CbGeAlD
Naproxen—AKR1C3—bone marrow—acquired immunodeficiency syndrome	0.000678	0.029	CbGeAlD
Naproxen—PTGS1—blood plasma—acquired immunodeficiency syndrome	0.000676	0.0289	CbGeAlD
Naproxen—AKR1C3—spinal cord—acquired immunodeficiency syndrome	0.000675	0.0288	CbGeAlD
Naproxen—AKR1C3—vagina—acquired immunodeficiency syndrome	0.000649	0.0277	CbGeAlD
Naproxen—PTGS2—blood plasma—acquired immunodeficiency syndrome	0.000647	0.0276	CbGeAlD
Naproxen—UGT1A1—blood—acquired immunodeficiency syndrome	0.000646	0.0276	CbGeAlD
Naproxen—AKR1C3—lung—acquired immunodeficiency syndrome	0.000614	0.0262	CbGeAlD
Naproxen—SLCO1A2—digestive system—acquired immunodeficiency syndrome	0.000459	0.0196	CbGeAlD
Naproxen—AKR1C3—brain—acquired immunodeficiency syndrome	0.000435	0.0186	CbGeAlD
Naproxen—SLC22A6—brain—acquired immunodeficiency syndrome	0.000433	0.0185	CbGeAlD
Naproxen—SLCO1A2—spinal cord—acquired immunodeficiency syndrome	0.000421	0.018	CbGeAlD
Naproxen—AKR1C3—lymph node—acquired immunodeficiency syndrome	0.00042	0.0179	CbGeAlD
Naproxen—SLCO1A2—lung—acquired immunodeficiency syndrome	0.000383	0.0164	CbGeAlD
Naproxen—SLCO1A2—nervous system—acquired immunodeficiency syndrome	0.000355	0.0152	CbGeAlD
Naproxen—SLCO1A2—central nervous system—acquired immunodeficiency syndrome	0.000342	0.0146	CbGeAlD
Naproxen—PTGS1—skin of body—acquired immunodeficiency syndrome	0.000325	0.0139	CbGeAlD
Naproxen—PTGS2—skin of body—acquired immunodeficiency syndrome	0.000311	0.0133	CbGeAlD
Naproxen—CYP2C8—blood—acquired immunodeficiency syndrome	0.000306	0.0131	CbGeAlD
Naproxen—CYP1A2—digestive system—acquired immunodeficiency syndrome	0.0003	0.0128	CbGeAlD
Naproxen—CYP1A2—blood—acquired immunodeficiency syndrome	0.000286	0.0122	CbGeAlD
Naproxen—CYP2C9—digestive system—acquired immunodeficiency syndrome	0.000285	0.0122	CbGeAlD
Naproxen—CYP2C8—vagina—acquired immunodeficiency syndrome	0.000283	0.0121	CbGeAlD
Naproxen—Fenoprofen—ALB—acquired immunodeficiency syndrome	0.000277	0.281	CrCbGaD
Naproxen—CYP2C9—blood—acquired immunodeficiency syndrome	0.000271	0.0116	CbGeAlD
Naproxen—SLCO1A2—brain—acquired immunodeficiency syndrome	0.000271	0.0116	CbGeAlD
Naproxen—ALB—brain—acquired immunodeficiency syndrome	0.00027	0.0115	CbGeAlD
Naproxen—ALB—lymph node—acquired immunodeficiency syndrome	0.000261	0.0111	CbGeAlD
Naproxen—PTGS1—digestive system—acquired immunodeficiency syndrome	0.00026	0.0111	CbGeAlD
Naproxen—PTGS2—lymphoid tissue—acquired immunodeficiency syndrome	0.000252	0.0108	CbGeAlD
Naproxen—CYP1A2—lung—acquired immunodeficiency syndrome	0.000251	0.0107	CbGeAlD
Naproxen—PTGS2—digestive system—acquired immunodeficiency syndrome	0.000249	0.0106	CbGeAlD
Naproxen—PTGS1—blood—acquired immunodeficiency syndrome	0.000248	0.0106	CbGeAlD
Naproxen—PTGS1—spinal cord—acquired immunodeficiency syndrome	0.000239	0.0102	CbGeAlD
Naproxen—PTGS2—blood—acquired immunodeficiency syndrome	0.000237	0.0101	CbGeAlD
Naproxen—PTGS1—vagina—acquired immunodeficiency syndrome	0.00023	0.00982	CbGeAlD
Naproxen—PTGS2—bone marrow—acquired immunodeficiency syndrome	0.000229	0.00979	CbGeAlD
Naproxen—PTGS2—spinal cord—acquired immunodeficiency syndrome	0.000228	0.00975	CbGeAlD
Naproxen—PTGS2—vagina—acquired immunodeficiency syndrome	0.00022	0.00938	CbGeAlD
Naproxen—PTGS1—lung—acquired immunodeficiency syndrome	0.000217	0.00928	CbGeAlD
Naproxen—PTGS2—lung—acquired immunodeficiency syndrome	0.000208	0.00887	CbGeAlD
Naproxen—Indomethacin—ALB—acquired immunodeficiency syndrome	0.000205	0.207	CrCbGaD
Naproxen—PTGS1—nervous system—acquired immunodeficiency syndrome	0.000201	0.0086	CbGeAlD
Naproxen—PTGS1—central nervous system—acquired immunodeficiency syndrome	0.000194	0.00828	CbGeAlD
Naproxen—PTGS2—nervous system—acquired immunodeficiency syndrome	0.000192	0.00822	CbGeAlD
Naproxen—CYP2C8—brain—acquired immunodeficiency syndrome	0.00019	0.0081	CbGeAlD
Naproxen—PTGS2—central nervous system—acquired immunodeficiency syndrome	0.000185	0.00791	CbGeAlD
Naproxen—Flurbiprofen—ALB—acquired immunodeficiency syndrome	0.000181	0.183	CrCbGaD
Naproxen—Ketoprofen—ALB—acquired immunodeficiency syndrome	0.000164	0.166	CrCbGaD
Naproxen—Ibuprofen—ALB—acquired immunodeficiency syndrome	0.000161	0.163	CrCbGaD
Naproxen—PTGS1—brain—acquired immunodeficiency syndrome	0.000154	0.00657	CbGeAlD
Naproxen—PTGS1—lymph node—acquired immunodeficiency syndrome	0.000149	0.00635	CbGeAlD
Naproxen—PTGS2—brain—acquired immunodeficiency syndrome	0.000147	0.00628	CbGeAlD
Naproxen—PTGS2—lymph node—acquired immunodeficiency syndrome	0.000142	0.00607	CbGeAlD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	6.26e-05	0.000335	CcSEcCtD
Naproxen—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	6.24e-05	0.000334	CcSEcCtD
Naproxen—Pruritus—Abacavir—acquired immunodeficiency syndrome	6.24e-05	0.000334	CcSEcCtD
Naproxen—Fatigue—Indinavir—acquired immunodeficiency syndrome	6.24e-05	0.000334	CcSEcCtD
Naproxen—Anorexia—Delavirdine—acquired immunodeficiency syndrome	6.23e-05	0.000333	CcSEcCtD
Naproxen—Discomfort—Ritonavir—acquired immunodeficiency syndrome	6.23e-05	0.000333	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	6.23e-05	0.000333	CcSEcCtD
Naproxen—Cough—Saquinavir—acquired immunodeficiency syndrome	6.22e-05	0.000333	CcSEcCtD
Naproxen—Angioedema—Lamivudine—acquired immunodeficiency syndrome	6.22e-05	0.000332	CcSEcCtD
Naproxen—Pain—Indinavir—acquired immunodeficiency syndrome	6.19e-05	0.000331	CcSEcCtD
Naproxen—Constipation—Indinavir—acquired immunodeficiency syndrome	6.19e-05	0.000331	CcSEcCtD
Naproxen—Insomnia—Efavirenz—acquired immunodeficiency syndrome	6.18e-05	0.000331	CcSEcCtD
Naproxen—Urticaria—Zidovudine—acquired immunodeficiency syndrome	6.18e-05	0.00033	CcSEcCtD
Naproxen—Convulsion—Saquinavir—acquired immunodeficiency syndrome	6.18e-05	0.00033	CcSEcCtD
Naproxen—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	6.17e-05	0.00033	CcSEcCtD
Naproxen—Hypertension—Saquinavir—acquired immunodeficiency syndrome	6.16e-05	0.000329	CcSEcCtD
Naproxen—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	6.15e-05	0.000329	CcSEcCtD
Naproxen—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	6.15e-05	0.000329	CcSEcCtD
Naproxen—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	6.14e-05	0.000328	CcSEcCtD
Naproxen—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	6.14e-05	0.000328	CcSEcCtD
Naproxen—Malaise—Lamivudine—acquired immunodeficiency syndrome	6.13e-05	0.000328	CcSEcCtD
Naproxen—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	6.12e-05	0.000327	CcSEcCtD
Naproxen—Nausea—Didanosine—acquired immunodeficiency syndrome	6.12e-05	0.000327	CcSEcCtD
Naproxen—Vertigo—Lamivudine—acquired immunodeficiency syndrome	6.11e-05	0.000327	CcSEcCtD
Naproxen—Hypotension—Delavirdine—acquired immunodeficiency syndrome	6.11e-05	0.000327	CcSEcCtD
Naproxen—Syncope—Lamivudine—acquired immunodeficiency syndrome	6.1e-05	0.000326	CcSEcCtD
Naproxen—Confusional state—Ritonavir—acquired immunodeficiency syndrome	6.1e-05	0.000326	CcSEcCtD
Naproxen—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	6.09e-05	0.000326	CcSEcCtD
Naproxen—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	6.09e-05	0.000326	CcSEcCtD
Naproxen—Somnolence—Efavirenz—acquired immunodeficiency syndrome	6.08e-05	0.000325	CcSEcCtD
Naproxen—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	6.07e-05	0.000325	CcSEcCtD
Naproxen—Myalgia—Saquinavir—acquired immunodeficiency syndrome	6.07e-05	0.000325	CcSEcCtD
Naproxen—Chest pain—Saquinavir—acquired immunodeficiency syndrome	6.07e-05	0.000325	CcSEcCtD
Naproxen—Anxiety—Saquinavir—acquired immunodeficiency syndrome	6.05e-05	0.000324	CcSEcCtD
Naproxen—Oedema—Ritonavir—acquired immunodeficiency syndrome	6.05e-05	0.000323	CcSEcCtD
Naproxen—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	6.03e-05	0.000323	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	6.03e-05	0.000322	CcSEcCtD
Naproxen—Dyspepsia—Efavirenz—acquired immunodeficiency syndrome	6.02e-05	0.000322	CcSEcCtD
Naproxen—Discomfort—Saquinavir—acquired immunodeficiency syndrome	6e-05	0.000321	CcSEcCtD
Naproxen—Loss of consciousness—Lamivudine—acquired immunodeficiency syndrome	5.98e-05	0.00032	CcSEcCtD
Naproxen—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	5.96e-05	0.000319	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	5.96e-05	0.000319	CcSEcCtD
Naproxen—Shock—Ritonavir—acquired immunodeficiency syndrome	5.95e-05	0.000318	CcSEcCtD
Naproxen—Decreased appetite—Efavirenz—acquired immunodeficiency syndrome	5.94e-05	0.000318	CcSEcCtD
Naproxen—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	5.94e-05	0.000318	CcSEcCtD
Naproxen—Cough—Lamivudine—acquired immunodeficiency syndrome	5.94e-05	0.000318	CcSEcCtD
Naproxen—Dizziness—Nelfinavir—acquired immunodeficiency syndrome	5.94e-05	0.000317	CcSEcCtD
Naproxen—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	5.93e-05	0.000317	CcSEcCtD
Naproxen—Thrombocytopenia—Ritonavir—acquired immunodeficiency syndrome	5.92e-05	0.000317	CcSEcCtD
Naproxen—Dizziness—Stavudine—acquired immunodeficiency syndrome	5.92e-05	0.000316	CcSEcCtD
Naproxen—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	5.91e-05	0.000316	CcSEcCtD
Naproxen—Insomnia—Delavirdine—acquired immunodeficiency syndrome	5.91e-05	0.000316	CcSEcCtD
Naproxen—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	5.9e-05	0.000316	CcSEcCtD
Naproxen—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	5.9e-05	0.000316	CcSEcCtD
Naproxen—Convulsion—Lamivudine—acquired immunodeficiency syndrome	5.89e-05	0.000315	CcSEcCtD
Naproxen—Vomiting—Nevirapine—acquired immunodeficiency syndrome	5.89e-05	0.000315	CcSEcCtD
Naproxen—Fatigue—Efavirenz—acquired immunodeficiency syndrome	5.89e-05	0.000315	CcSEcCtD
Naproxen—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	5.87e-05	0.000314	CcSEcCtD
Naproxen—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	5.87e-05	0.000314	CcSEcCtD
Naproxen—Confusional state—Saquinavir—acquired immunodeficiency syndrome	5.87e-05	0.000314	CcSEcCtD
Naproxen—Hyperhidrosis—Ritonavir—acquired immunodeficiency syndrome	5.85e-05	0.000313	CcSEcCtD
Naproxen—Pain—Efavirenz—acquired immunodeficiency syndrome	5.84e-05	0.000313	CcSEcCtD
Naproxen—Constipation—Efavirenz—acquired immunodeficiency syndrome	5.84e-05	0.000313	CcSEcCtD
Naproxen—Rash—Nevirapine—acquired immunodeficiency syndrome	5.84e-05	0.000313	CcSEcCtD
Naproxen—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	5.84e-05	0.000312	CcSEcCtD
Naproxen—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	5.83e-05	0.000312	CcSEcCtD
Naproxen—Dizziness—Abacavir—acquired immunodeficiency syndrome	5.83e-05	0.000312	CcSEcCtD
Naproxen—Oedema—Saquinavir—acquired immunodeficiency syndrome	5.82e-05	0.000311	CcSEcCtD
Naproxen—Somnolence—Delavirdine—acquired immunodeficiency syndrome	5.81e-05	0.000311	CcSEcCtD
Naproxen—Headache—Nevirapine—acquired immunodeficiency syndrome	5.81e-05	0.000311	CcSEcCtD
Naproxen—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	5.79e-05	0.00031	CcSEcCtD
Naproxen—Chest pain—Lamivudine—acquired immunodeficiency syndrome	5.79e-05	0.00031	CcSEcCtD
Naproxen—Myalgia—Lamivudine—acquired immunodeficiency syndrome	5.79e-05	0.00031	CcSEcCtD
Naproxen—Infection—Saquinavir—acquired immunodeficiency syndrome	5.78e-05	0.000309	CcSEcCtD
Naproxen—Anxiety—Lamivudine—acquired immunodeficiency syndrome	5.77e-05	0.000309	CcSEcCtD
Naproxen—Anorexia—Ritonavir—acquired immunodeficiency syndrome	5.76e-05	0.000308	CcSEcCtD
Naproxen—Dyspepsia—Delavirdine—acquired immunodeficiency syndrome	5.76e-05	0.000308	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	5.75e-05	0.000308	CcSEcCtD
Naproxen—Urticaria—Indinavir—acquired immunodeficiency syndrome	5.75e-05	0.000307	CcSEcCtD
Naproxen—Shock—Saquinavir—acquired immunodeficiency syndrome	5.73e-05	0.000306	CcSEcCtD
Naproxen—Discomfort—Lamivudine—acquired immunodeficiency syndrome	5.72e-05	0.000306	CcSEcCtD
Naproxen—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	5.72e-05	0.000306	CcSEcCtD
Naproxen—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	5.72e-05	0.000306	CcSEcCtD
Naproxen—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	5.71e-05	0.000305	CcSEcCtD
Naproxen—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	5.71e-05	0.000305	CcSEcCtD
Naproxen—Thrombocytopenia—Saquinavir—acquired immunodeficiency syndrome	5.7e-05	0.000305	CcSEcCtD
Naproxen—Vomiting—Stavudine—acquired immunodeficiency syndrome	5.69e-05	0.000304	CcSEcCtD
Naproxen—Decreased appetite—Delavirdine—acquired immunodeficiency syndrome	5.68e-05	0.000304	CcSEcCtD
Naproxen—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	5.66e-05	0.000303	CcSEcCtD
Naproxen—Rash—Nelfinavir—acquired immunodeficiency syndrome	5.66e-05	0.000303	CcSEcCtD
Naproxen—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	5.65e-05	0.000302	CcSEcCtD
Naproxen—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	5.65e-05	0.000302	CcSEcCtD
Naproxen—Hypotension—Ritonavir—acquired immunodeficiency syndrome	5.65e-05	0.000302	CcSEcCtD
Naproxen—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	5.65e-05	0.000302	CcSEcCtD
Naproxen—Rash—Stavudine—acquired immunodeficiency syndrome	5.64e-05	0.000302	CcSEcCtD
Naproxen—Fatigue—Delavirdine—acquired immunodeficiency syndrome	5.64e-05	0.000302	CcSEcCtD
Naproxen—Dermatitis—Stavudine—acquired immunodeficiency syndrome	5.64e-05	0.000301	CcSEcCtD
Naproxen—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	5.63e-05	0.000301	CcSEcCtD
Naproxen—Hyperhidrosis—Saquinavir—acquired immunodeficiency syndrome	5.63e-05	0.000301	CcSEcCtD
Naproxen—Headache—Nelfinavir—acquired immunodeficiency syndrome	5.62e-05	0.000301	CcSEcCtD
Naproxen—Headache—Stavudine—acquired immunodeficiency syndrome	5.61e-05	0.0003	CcSEcCtD
Naproxen—Vomiting—Abacavir—acquired immunodeficiency syndrome	5.61e-05	0.0003	CcSEcCtD
Naproxen—Confusional state—Lamivudine—acquired immunodeficiency syndrome	5.6e-05	0.000299	CcSEcCtD
Naproxen—Pain—Delavirdine—acquired immunodeficiency syndrome	5.59e-05	0.000299	CcSEcCtD
Naproxen—Constipation—Delavirdine—acquired immunodeficiency syndrome	5.59e-05	0.000299	CcSEcCtD
Naproxen—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	5.59e-05	0.000299	CcSEcCtD
Naproxen—Asthenia—Zidovudine—acquired immunodeficiency syndrome	5.58e-05	0.000298	CcSEcCtD
Naproxen—Rash—Abacavir—acquired immunodeficiency syndrome	5.56e-05	0.000297	CcSEcCtD
Naproxen—Dermatitis—Abacavir—acquired immunodeficiency syndrome	5.55e-05	0.000297	CcSEcCtD
Naproxen—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	5.55e-05	0.000297	CcSEcCtD
Naproxen—Oedema—Lamivudine—acquired immunodeficiency syndrome	5.55e-05	0.000297	CcSEcCtD
Naproxen—Anorexia—Saquinavir—acquired immunodeficiency syndrome	5.55e-05	0.000297	CcSEcCtD
Naproxen—Headache—Abacavir—acquired immunodeficiency syndrome	5.52e-05	0.000295	CcSEcCtD
Naproxen—Infection—Lamivudine—acquired immunodeficiency syndrome	5.52e-05	0.000295	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	5.51e-05	0.000295	CcSEcCtD
Naproxen—Nausea—Nevirapine—acquired immunodeficiency syndrome	5.51e-05	0.000294	CcSEcCtD
Naproxen—Pruritus—Zidovudine—acquired immunodeficiency syndrome	5.5e-05	0.000294	CcSEcCtD
Naproxen—Insomnia—Ritonavir—acquired immunodeficiency syndrome	5.47e-05	0.000293	CcSEcCtD
Naproxen—Shock—Lamivudine—acquired immunodeficiency syndrome	5.46e-05	0.000292	CcSEcCtD
Naproxen—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	5.44e-05	0.000291	CcSEcCtD
Naproxen—Hypotension—Saquinavir—acquired immunodeficiency syndrome	5.44e-05	0.000291	CcSEcCtD
Naproxen—Thrombocytopenia—Lamivudine—acquired immunodeficiency syndrome	5.44e-05	0.000291	CcSEcCtD
Naproxen—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	5.43e-05	0.00029	CcSEcCtD
Naproxen—Urticaria—Efavirenz—acquired immunodeficiency syndrome	5.43e-05	0.00029	CcSEcCtD
Naproxen—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	5.4e-05	0.000289	CcSEcCtD
Naproxen—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	5.4e-05	0.000289	CcSEcCtD
Naproxen—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	5.39e-05	0.000288	CcSEcCtD
Naproxen—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	5.39e-05	0.000288	CcSEcCtD
Naproxen—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	5.39e-05	0.000288	CcSEcCtD
Naproxen—Somnolence—Ritonavir—acquired immunodeficiency syndrome	5.38e-05	0.000288	CcSEcCtD
Naproxen—Hyperhidrosis—Lamivudine—acquired immunodeficiency syndrome	5.37e-05	0.000287	CcSEcCtD
Naproxen—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	5.35e-05	0.000286	CcSEcCtD
Naproxen—Nausea—Nelfinavir—acquired immunodeficiency syndrome	5.33e-05	0.000285	CcSEcCtD
Naproxen—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	5.33e-05	0.000285	CcSEcCtD
Naproxen—Dyspepsia—Ritonavir—acquired immunodeficiency syndrome	5.32e-05	0.000285	CcSEcCtD
Naproxen—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	5.32e-05	0.000285	CcSEcCtD
Naproxen—Nausea—Stavudine—acquired immunodeficiency syndrome	5.32e-05	0.000284	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	5.3e-05	0.000284	CcSEcCtD
Naproxen—Anorexia—Lamivudine—acquired immunodeficiency syndrome	5.29e-05	0.000283	CcSEcCtD
Naproxen—Insomnia—Saquinavir—acquired immunodeficiency syndrome	5.26e-05	0.000282	CcSEcCtD
Naproxen—Decreased appetite—Ritonavir—acquired immunodeficiency syndrome	5.26e-05	0.000281	CcSEcCtD
Naproxen—Nausea—Abacavir—acquired immunodeficiency syndrome	5.24e-05	0.00028	CcSEcCtD
Naproxen—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	5.23e-05	0.00028	CcSEcCtD
Naproxen—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	5.22e-05	0.000279	CcSEcCtD
Naproxen—Fatigue—Ritonavir—acquired immunodeficiency syndrome	5.21e-05	0.000279	CcSEcCtD
Naproxen—Urticaria—Delavirdine—acquired immunodeficiency syndrome	5.19e-05	0.000278	CcSEcCtD
Naproxen—Asthenia—Indinavir—acquired immunodeficiency syndrome	5.19e-05	0.000278	CcSEcCtD
Naproxen—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	5.19e-05	0.000278	CcSEcCtD
Naproxen—Hypotension—Lamivudine—acquired immunodeficiency syndrome	5.19e-05	0.000277	CcSEcCtD
Naproxen—Somnolence—Saquinavir—acquired immunodeficiency syndrome	5.17e-05	0.000277	CcSEcCtD
Naproxen—Constipation—Ritonavir—acquired immunodeficiency syndrome	5.17e-05	0.000277	CcSEcCtD
Naproxen—Pain—Ritonavir—acquired immunodeficiency syndrome	5.17e-05	0.000277	CcSEcCtD
Naproxen—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	5.17e-05	0.000276	CcSEcCtD
Naproxen—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	5.17e-05	0.000276	CcSEcCtD
Naproxen—Dizziness—Zidovudine—acquired immunodeficiency syndrome	5.14e-05	0.000275	CcSEcCtD
Naproxen—Dyspepsia—Saquinavir—acquired immunodeficiency syndrome	5.12e-05	0.000274	CcSEcCtD
Naproxen—Pruritus—Indinavir—acquired immunodeficiency syndrome	5.12e-05	0.000274	CcSEcCtD
Naproxen—Decreased appetite—Saquinavir—acquired immunodeficiency syndrome	5.06e-05	0.000271	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	5.06e-05	0.000271	CcSEcCtD
Naproxen—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	5.04e-05	0.000269	CcSEcCtD
Naproxen—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	5.02e-05	0.000269	CcSEcCtD
Naproxen—Insomnia—Lamivudine—acquired immunodeficiency syndrome	5.02e-05	0.000269	CcSEcCtD
Naproxen—Fatigue—Saquinavir—acquired immunodeficiency syndrome	5.02e-05	0.000268	CcSEcCtD
Naproxen—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	4.99e-05	0.000267	CcSEcCtD
Naproxen—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	4.98e-05	0.000267	CcSEcCtD
Naproxen—Pain—Saquinavir—acquired immunodeficiency syndrome	4.98e-05	0.000266	CcSEcCtD
Naproxen—Constipation—Saquinavir—acquired immunodeficiency syndrome	4.98e-05	0.000266	CcSEcCtD
Naproxen—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	4.95e-05	0.000265	CcSEcCtD
Naproxen—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	4.95e-05	0.000265	CcSEcCtD
Naproxen—Vomiting—Zidovudine—acquired immunodeficiency syndrome	4.95e-05	0.000264	CcSEcCtD
Naproxen—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	4.94e-05	0.000264	CcSEcCtD
Naproxen—Somnolence—Lamivudine—acquired immunodeficiency syndrome	4.94e-05	0.000264	CcSEcCtD
Naproxen—Rash—Zidovudine—acquired immunodeficiency syndrome	4.9e-05	0.000262	CcSEcCtD
Naproxen—Asthenia—Efavirenz—acquired immunodeficiency syndrome	4.9e-05	0.000262	CcSEcCtD
Naproxen—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	4.9e-05	0.000262	CcSEcCtD
Naproxen—Dyspepsia—Lamivudine—acquired immunodeficiency syndrome	4.89e-05	0.000261	CcSEcCtD
Naproxen—Headache—Zidovudine—acquired immunodeficiency syndrome	4.87e-05	0.000261	CcSEcCtD
Naproxen—Pruritus—Efavirenz—acquired immunodeficiency syndrome	4.84e-05	0.000259	CcSEcCtD
Naproxen—Decreased appetite—Lamivudine—acquired immunodeficiency syndrome	4.83e-05	0.000258	CcSEcCtD
Naproxen—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	4.82e-05	0.000258	CcSEcCtD
Naproxen—Urticaria—Ritonavir—acquired immunodeficiency syndrome	4.8e-05	0.000257	CcSEcCtD
Naproxen—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	4.8e-05	0.000257	CcSEcCtD
Naproxen—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	4.79e-05	0.000256	CcSEcCtD
Naproxen—Fatigue—Lamivudine—acquired immunodeficiency syndrome	4.79e-05	0.000256	CcSEcCtD
Naproxen—Dizziness—Indinavir—acquired immunodeficiency syndrome	4.78e-05	0.000256	CcSEcCtD
Naproxen—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	4.78e-05	0.000256	CcSEcCtD
Naproxen—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	4.78e-05	0.000256	CcSEcCtD
Naproxen—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	4.76e-05	0.000255	CcSEcCtD
Naproxen—Pain—Lamivudine—acquired immunodeficiency syndrome	4.75e-05	0.000254	CcSEcCtD
Naproxen—Constipation—Lamivudine—acquired immunodeficiency syndrome	4.75e-05	0.000254	CcSEcCtD
Naproxen—Asthenia—Delavirdine—acquired immunodeficiency syndrome	4.69e-05	0.000251	CcSEcCtD
Naproxen—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	4.68e-05	0.00025	CcSEcCtD
Naproxen—Pruritus—Delavirdine—acquired immunodeficiency syndrome	4.63e-05	0.000247	CcSEcCtD
Naproxen—Urticaria—Saquinavir—acquired immunodeficiency syndrome	4.62e-05	0.000247	CcSEcCtD
Naproxen—Nausea—Zidovudine—acquired immunodeficiency syndrome	4.62e-05	0.000247	CcSEcCtD
Naproxen—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	4.6e-05	0.000246	CcSEcCtD
Naproxen—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	4.6e-05	0.000246	CcSEcCtD
Naproxen—Vomiting—Indinavir—acquired immunodeficiency syndrome	4.6e-05	0.000246	CcSEcCtD
Naproxen—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	4.58e-05	0.000245	CcSEcCtD
Naproxen—Rash—Indinavir—acquired immunodeficiency syndrome	4.56e-05	0.000244	CcSEcCtD
Naproxen—Dermatitis—Indinavir—acquired immunodeficiency syndrome	4.56e-05	0.000244	CcSEcCtD
Naproxen—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	4.54e-05	0.000243	CcSEcCtD
Naproxen—Headache—Indinavir—acquired immunodeficiency syndrome	4.53e-05	0.000242	CcSEcCtD
Naproxen—Dizziness—Efavirenz—acquired immunodeficiency syndrome	4.52e-05	0.000242	CcSEcCtD
Naproxen—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	4.47e-05	0.000239	CcSEcCtD
Naproxen—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	4.46e-05	0.000238	CcSEcCtD
Naproxen—Urticaria—Lamivudine—acquired immunodeficiency syndrome	4.41e-05	0.000236	CcSEcCtD
Naproxen—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	4.39e-05	0.000235	CcSEcCtD
Naproxen—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	4.39e-05	0.000235	CcSEcCtD
Naproxen—Vomiting—Efavirenz—acquired immunodeficiency syndrome	4.35e-05	0.000232	CcSEcCtD
Naproxen—Asthenia—Ritonavir—acquired immunodeficiency syndrome	4.34e-05	0.000232	CcSEcCtD
Naproxen—Dizziness—Delavirdine—acquired immunodeficiency syndrome	4.32e-05	0.000231	CcSEcCtD
Naproxen—Rash—Efavirenz—acquired immunodeficiency syndrome	4.31e-05	0.00023	CcSEcCtD
Naproxen—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	4.31e-05	0.00023	CcSEcCtD
Naproxen—Nausea—Indinavir—acquired immunodeficiency syndrome	4.3e-05	0.00023	CcSEcCtD
Naproxen—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	4.29e-05	0.000229	CcSEcCtD
Naproxen—Headache—Efavirenz—acquired immunodeficiency syndrome	4.28e-05	0.000229	CcSEcCtD
Naproxen—Pruritus—Ritonavir—acquired immunodeficiency syndrome	4.28e-05	0.000229	CcSEcCtD
Naproxen—Asthenia—Saquinavir—acquired immunodeficiency syndrome	4.18e-05	0.000223	CcSEcCtD
Naproxen—Vomiting—Delavirdine—acquired immunodeficiency syndrome	4.16e-05	0.000222	CcSEcCtD
Naproxen—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	4.14e-05	0.000221	CcSEcCtD
Naproxen—Rash—Delavirdine—acquired immunodeficiency syndrome	4.12e-05	0.000221	CcSEcCtD
Naproxen—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	4.12e-05	0.00022	CcSEcCtD
Naproxen—Pruritus—Saquinavir—acquired immunodeficiency syndrome	4.12e-05	0.00022	CcSEcCtD
Naproxen—Headache—Delavirdine—acquired immunodeficiency syndrome	4.1e-05	0.000219	CcSEcCtD
Naproxen—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	4.09e-05	0.000219	CcSEcCtD
Naproxen—Nausea—Efavirenz—acquired immunodeficiency syndrome	4.06e-05	0.000217	CcSEcCtD
Naproxen—Dizziness—Ritonavir—acquired immunodeficiency syndrome	4e-05	0.000214	CcSEcCtD
Naproxen—Asthenia—Lamivudine—acquired immunodeficiency syndrome	3.98e-05	0.000213	CcSEcCtD
Naproxen—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	3.98e-05	0.000213	CcSEcCtD
Naproxen—Pruritus—Lamivudine—acquired immunodeficiency syndrome	3.93e-05	0.00021	CcSEcCtD
Naproxen—Nausea—Delavirdine—acquired immunodeficiency syndrome	3.88e-05	0.000208	CcSEcCtD
Naproxen—Dizziness—Saquinavir—acquired immunodeficiency syndrome	3.85e-05	0.000206	CcSEcCtD
Naproxen—Vomiting—Ritonavir—acquired immunodeficiency syndrome	3.84e-05	0.000206	CcSEcCtD
Naproxen—Rash—Ritonavir—acquired immunodeficiency syndrome	3.81e-05	0.000204	CcSEcCtD
Naproxen—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	3.81e-05	0.000204	CcSEcCtD
Naproxen—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	3.8e-05	0.000203	CcSEcCtD
Naproxen—Headache—Ritonavir—acquired immunodeficiency syndrome	3.79e-05	0.000203	CcSEcCtD
Naproxen—Vomiting—Saquinavir—acquired immunodeficiency syndrome	3.7e-05	0.000198	CcSEcCtD
Naproxen—Dizziness—Lamivudine—acquired immunodeficiency syndrome	3.67e-05	0.000196	CcSEcCtD
Naproxen—Rash—Saquinavir—acquired immunodeficiency syndrome	3.67e-05	0.000196	CcSEcCtD
Naproxen—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	3.67e-05	0.000196	CcSEcCtD
Naproxen—Headache—Saquinavir—acquired immunodeficiency syndrome	3.65e-05	0.000195	CcSEcCtD
Naproxen—Nausea—Ritonavir—acquired immunodeficiency syndrome	3.59e-05	0.000192	CcSEcCtD
Naproxen—Vomiting—Lamivudine—acquired immunodeficiency syndrome	3.53e-05	0.000189	CcSEcCtD
Naproxen—Rash—Lamivudine—acquired immunodeficiency syndrome	3.5e-05	0.000187	CcSEcCtD
Naproxen—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	3.5e-05	0.000187	CcSEcCtD
Naproxen—Headache—Lamivudine—acquired immunodeficiency syndrome	3.48e-05	0.000186	CcSEcCtD
Naproxen—Nausea—Saquinavir—acquired immunodeficiency syndrome	3.46e-05	0.000185	CcSEcCtD
Naproxen—Nausea—Lamivudine—acquired immunodeficiency syndrome	3.3e-05	0.000176	CcSEcCtD
